Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac392 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Nusrat J Epsi und 36 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Scienc…. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Defense Health Program.
Abstract (Originalsprache)
Background
Comparison of humoral responses in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinees, those with SARS-CoV-2 infection, or combinations of vaccine/ infection (“hybrid immunity”) may clarify predictors of vaccine immunogenicity.
Methods
We studied 2660 US Military Health System beneficiaries with a history of SARS-CoV-2 infection-alone (n = 705), vaccination-alone (n = 932), vaccine-after-infection (n = 869), and vaccine-breakthrough-infection (n = 154). Peak anti-spike–immunoglobulin G (IgG) responses through 183 days were compared, with adjustment for vaccine product, demography, and comorbidities. We excluded those with evidence of clinical or subclinical SARS-CoV-2 reinfection from all groups.
Results
Multivariable regression results indicated that vaccine-after-infection anti-spike–IgG responses were higher than infection-alone (P < .01), regardless of prior infection severity. An increased time between infection and vaccination was associated with greater post-vaccination IgG response (P < .01). Vaccination-alone elicited a greater IgG response but more rapid waning of IgG (P < .01) compared with infection-alone (P < .01). BNT162b2 and mRNA-1273 vaccine-receipt was associated with greater IgG responses compared with JNJ-78436735 vaccine-receipt (P < .01), regardless of infection history. Those with vaccine-after-infection or vaccine-breakthrough-infection had a more durable anti-spike–IgG response compared to infection-alone (P < .01).
Conclusions
Vaccine-receipt elicited higher anti-spike–IgG responses than infection-alone, although IgG levels waned faster in those vaccinated (compared to infection-alone). Vaccine-after-infection elicits a greater humoral response compared with vaccine or infection alone; and the timing, but not disease severity, of prior infection predicted these post-vaccination IgG responses. While differences between groups were small in magnitude, these results offer insights into vaccine immunogenicity variations that may help inform vaccination timing strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc, Bethesda, Maryland, USA.
- Brooke Army Medical Center, Fort Sam Houston, Texas, USA.
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
- Naval Medical Center Portsmouth, Portsmouth, Virginia, USA.
ORCID-Profile: Nusrat J Epsi, Tahaniyat Lalani, Ryan C Maves
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- Defense Health Program
- Infectious Disease Clinical Research Program
- Department of Defense
- USUHS
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- National Institutes of Health
Zitieren
APA
Epsi, N. J., Richard, S. A., Lindholm, D. A., Mende, K., Ganesan, A., Huprikar, N., Lalani, T., Fries, A. C., Maves, R. C., Colombo, R. E., Larson, D. T., Smith, A., Chi, S. W., Maldonado, C. J., Ewers, E. C., Jones, M. U., Berjohn, C. M., Libraty, D. H., Edwards, M. S., …, & Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential COVID-19 Cohort Study Group (2023). Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac392
Vancouver
Epsi NJ, Richard SA, Lindholm DA, Mende K, Ganesan A, Huprikar N, et al. Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac392
BibTeX
@article{Epsi2023,
author = {Epsi, Nusrat J and Richard, Stephanie A and Lindholm, David A and Mende, Katrin and Ganesan, Anuradha and Huprikar, Nikhil and Lalani, Tahaniyat and Fries, Anthony C and Maves, Ryan C and Colombo, Rhonda E and Larson, Derek T and Smith, Alfred and Chi, Sharon W and Maldonado, Carlos J and Ewers, Evan C and Jones, Milissa U and Berjohn, Catherine M and Libraty, Daniel H and Edwards, Margaret Sanchez and English, Caroline and Rozman, Julia S and Mody, Rupal M and Colombo, Christopher J and Samuels, Emily C and Nwachukwu, Princess and Tso, Marana S and Scher, Ann I and Byrne, Celia and Rusiecki, Jennifer and Simons, Mark P and Tribble, David and Broder, Christopher C and Agan, Brian K and Burgess, Timothy H and Laing, Eric D and Pollett, Simon D and Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential COVID-19 Cohort Study Group, Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential COVID-19 Cohort Study Group},
title = {Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac392}
}
EUVIMED